文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

CD19嵌合抗原受体T细胞免疫治疗中枢神经系统白血病:两例报告及文献复习

[Treatment of central nervous system leukemia with CD19-chimeric antigen receptor T-cell immunotherapy: two cases report and literature review].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

报道两例合并中枢神经系统白血病(CNSL)患者接受抗CD19 CAR-T细胞治疗的过程与结果,输注总量均为5.0×10(6)/kg。回输后两例中枢神经系统症状均缓解,例1影像学异常消失但出现细胞因子释放综合征(CRS),药物干预后好转;例2脑脊液微小残留病转阴且未出现明显CRS反应。结论认为CAR-T细胞治疗有望缓解CNSL并改善预后。

要点

  • 两例CNSL患者接受抗CD19 CAR-T细胞治疗,输注总量均为5.0×10(6)/kg。
  • 回输后两例中枢神经系统症状均缓解,例1影像学异常消失、例2脑脊液微小残留病转阴。
  • 例1治疗过程中出现CRS,药物干预后好转;例2未出现明显CRS反应。

核心结论

  • CAR-T细胞治疗有望缓解CNSL,改善患者预后。

研究设计与样本

  • 两例合并CNSL的白血病患者接受抗CD19 CAR-T细胞治疗,报道整个治疗过程与结果并进行相关文献复习。

主要发现

  • 两例患者骨髓细胞形态学特征分别为伴B淋系表达的急性髓系白血病(AML)-M(2)和急性B淋巴细胞白血病(B-ALL),免疫分型符合相应异常表现。
  • 两例临床和实验室检查符合CNSL诊断标准,诊断明确后予以抗CD19 CAR-T细胞治疗,输注总量均为5.0×10(6)/kg。
  • 回输后两例患者中枢神经系统症状缓解;例1影像学异常消失,治疗过程中出现细胞因子释放综合征(CRS),药物干预后好转。
  • 例2脑脊液微小残留病转阴,未出现明显CRS反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the efficacy and safety of chimeric antigen receptor T (CAR-T) cells in the treatment of central nervous system leukemia (CNSL). Methods: Two leukemia patients with CNSL were treated with CD19-CAR-T cells. The process and results of the entire treatment is reported and related literature review is conducted. Results: The patients were diagnosed as acute myeloid leukemia (AML)-M(2) with B lymphoid antigen expression and B cell acute lymphoblastic leukemia(B-ALL) by morphology and immunophenotype assay. The immunophenotype was consistent with the abnormal manifestations of AML-M(2) and B-ALL. Their clinical manifestations and laboratory tests met the diagnostic criteria of CNSL. The diagnosis was clear and the two patients were treated with CD19-CAR-T cell immunotherapy. Central nervous system symptoms were relieved. The imaging abnormalities of patient one has disappeared but cytokines release syndrome (CRS) occurred during the treatment. Cerebrospinal fluid of patient two was negative and no obvious CRS reaction was found. Conclusions: CAR-T cell immunotherapy is likely to induce the remission of CNSL and improve the prognosis. 目的: 探讨CAR-T细胞治疗中枢神经系统白血病(CNSL)的有效性和安全性。 方法: 报道两例合并CNSL白血病患者抗CD19 CAR-T细胞治疗的过程及结果,并对相关文献进行复习。 结果: 两例患者骨髓细胞形态学特征分别为伴B淋系表达的急性髓系白血病(AML)-M(2)和急性B淋巴细胞白血病(B-ALL),免疫分型符合AML-M(2)和B-ALL的异常表现,临床和实验室检查符合CNSL诊断标准,诊断明确后予以抗CD19 CAR-T细胞治疗,输注总量均为5.0×10(6)/kg。回输后两例患者中枢神经系统症状缓解。例1影像学异常消失,治疗过程中出现细胞因子释放综合征(CRS),药物干预后好转;例2脑脊液微小残留病转阴,未出现明显CRS反应。 结论: CAR-T细胞治疗有望缓解CNSL,改善患者预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jin MY, Han Y, Liu YJ, et al. [Treatment of central nervous system leukemia with CD19-chimeric antigen receptor T-cell immunotherapy: two cases report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30180466. doi:10.3760/cma.j.issn.0253-2727.2018.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。